BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37381778)

  • 1. Amyloidogenic light chains impair plasma cell survival.
    Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
    Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
    Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
    PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic Amyloidosis Due to Clonal Plasma Cell Diseases.
    Bianchi G; Kumar S
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1009-1026. PubMed ID: 33099420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
    Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
    FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
    Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
    Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
    Nevone A; Girelli M; Mangiacavalli S; Paiva B; Milani P; Cascino P; Piscitelli M; Speranzini V; Cartia CS; Benvenuti P; Goicoechea I; Fazio F; Basset M; Foli A; Nanci M; Mazzini G; Caminito S; Sesta MA; Casarini S; Rognoni P; Lavatelli F; Petrucci MT; Olimpieri PP; Ricagno S; Arcaini L; Merlini G; Palladini G; Nuvolone M
    Leukemia; 2022 Aug; 36(8):2076-2085. PubMed ID: 35610346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
    Ramirez-Alvarado M; Barnidge DR; Murray DL; Dispenzieri A; Marin-Argany M; Dick CJ; Cooper SA; Nasr SH; Ward CJ; Dasari S; Jiménez-Zepeda VH; Leung N
    Am J Hematol; 2017 Jun; 92(6):536-541. PubMed ID: 28295502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
    Oliva L; Orfanelli U; Resnati M; Raimondi A; Orsi A; Milan E; Palladini G; Milani P; Cerruti F; Cascio P; Casarini S; Rognoni P; Touvier T; Marcatti M; Ciceri F; Mangiacavalli S; Corso A; Merlini G; Cenci S
    Blood; 2017 Apr; 129(15):2132-2142. PubMed ID: 28130214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
    Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
    Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
    Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
    Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in the management of AL Amyloidosis.
    Kastritis E; Dimopoulos MA
    Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
    Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
    PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
    Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
    Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell Damage in Light Chain Amyloidosis: FIBRIL INTERNALIZATION, TOXICITY AND CELL-MEDIATED SEEDING.
    Marin-Argany M; Lin Y; Misra P; Williams A; Wall JS; Howell KG; Elsbernd LR; McClure M; Ramirez-Alvarado M
    J Biol Chem; 2016 Sep; 291(38):19813-25. PubMed ID: 27462073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
    Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
    Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies gone bad - the molecular mechanism of light chain amyloidosis.
    Absmeier RM; Rottenaicher GJ; Svilenov HL; Kazman P; Buchner J
    FEBS J; 2023 Mar; 290(6):1398-1419. PubMed ID: 35122394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
    Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
    J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Splenic plasma cells can serve as a source of amyloidogenic light chains.
    Solomon A; Macy SD; Wooliver C; Weiss DT; Westermark P
    Blood; 2009 Feb; 113(7):1501-3. PubMed ID: 19050307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.